+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

Visiongain Publishes Rare Diseases Market Report 2021-2031

02 March 2021
Pharma

Visiongain has published a new report on Rare Diseases Market Report 2021-2031: Forecasts by Drugs (Revlimid, MabThera/Rituxan, Opdivo, Imbruvica, Sprycel, Tasigna, Copaxone, Rebif), by Disease (Rare Oncology Diseases, Rare Metabolic Diseases, Rare Neurologic Diseases, Rare Haematology Diseases, Rare Infectious Diseases, Other Rare Diseases), by Type (Non Biologics, Biologics), by Age (Adult, Pediatric), by End-use (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.

According to Visiongain analysis, global rare diseases market is estimated to be valued at US$ xx billion in 2020. The global market is expected to witness a CAGR of xx% from 2021 to 2026 and is expected to reach US$ xx billion in 2026 from its previous value of US$ xx billion in 2021. Visiongain further anticipates that the global rare diseases market will reach US$ xx billion in 2031 while growing at a CAGR of xx% from 2021 to 2031.

COVID-19 Impact on Rare Disease Market
COVID-19 pandemic has wreaked havoc on the global economy and disrupted the flow of trade since the coronavirus spread in late 2019. As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.

Regional Analysis
Based on regions, the global rare diseases market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to Visiongain analysis, North America dominated the global rare diseases market and is predicted to do over the forecast period. The market dominance is attributed to due to high number of approved drugs, high awareness levels regarding diagnosis and management of diseases. Furthermore, government funds for geriatric population is also one of the major reason for North America being dominant across the globe. However, APAC region is projected to witness highest growth rate over the forecast period owing to increasing growth of prenatal as well as newborn screenings in countries such as India, Thailand, Singapore, and many more. Rising geriatric population coupled with increasing awareness regarding symptoms, diagnosis is anticipated to fuel the regional market over the study period.

Disease Analysis
On the basis of disease, the global rare disease market has been divided into has been segmented based on rare oncology diseases, rare metabolic diseases, rare neurologic diseases, rare hematology diseases, rare infectious diseases, other rare diseases. Rare Oncology Diseases segment dominated the global market by contributing xx in 2021 and is likely to grow at a CAGR of xx% from 2021-2031. The rare oncology segment is likely to grow owing to rising number of rare cancers coupled with large pool of clinical trials being conducted in the U.S. and Europe for the same.

Companies Profiled
1. Pfizer Inc.
2. Novartis AG
3. Merck KGaA
4. F. Hoffmann-La Roche Ltd.
5. Amgen Inc.
6. Biogen Inc.
7. Teva Pharmaceuticals
8. Alexion Pharmaceuticals, Inc.
9. Sanofi S.A.
10. AbbVie
11. Bristol Myers Squibb
12. Takeda Pharmaceuticals
13. Roche
14. Johnson & Johnson Services, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2022-2032

The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.

29 September 2022

Read

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

Read

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

Read

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever